Coagulopathy after cardiac surgery with cardiopulmonary bypass is a serious complication that may result in massive bleeding requiring transfusion of significant amounts of blood products, plasma, and platelets. In addition to increased patient morbidity and mortality it is associated with longer hospital stay and increased resource utilization. The current review discusses aspects in cardiopulmonary bypass–induced coagulopathy with emphasis on point-of-care testing and individualized “goal-directed” therapy in patients who develop excessive bleeding after cardiac surgery.
DykeCAronsonSDietrichW. Universal definition of perioperative bleeding in adult cardiac surgery [published online December 9, 2013]. J Thorac Cardiovasc Surg. doi:10.1016/j.jtcvs.2013.10.070.
2.
GörlingerKShore-LessersonLDirkmannDHankeAARahe-MeyerNTanakaKA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth. 2013;27(suppl 4):S20-S34.
3.
DespotisGEbyCLublinDM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion. 2008;48(1 suppl):2S-30S.
4.
MoultonMJCreswellLLMackeyMECoxJLRosenbloomM. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996;111:1037-1046.
5.
TanakaKABaderSOGörlingerK. Novel approaches in management of perioperative coagulopathy. Curr Opin Anaesthesiol. 2014;27:72-80.
6.
RanucciMBaryshnikovaECastelvecchioSPelisseroG; Surgical and Clinical Outcome Research (SCORE) Group. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg. 2013;96:478-485.
7.
ChristensenMCKrapfSKempelAvon HeymannC. Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg. 2009;138:687-693.
8.
KarkoutiKWijeysunderaDNYauTM. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004;44:1453-1462.
9.
KochCGLiLSesslerDI. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229-1239.
10.
Kozek-LangeneckerSAAfshariAAlbaladejoP. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J of Anaesthesiol. 2013;30:270-382.
11.
Society of Thoracic Surgeons Blood Conservation Guideline Task Force, FerrarisVABrownJR. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944-982.
12.
American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105:198-208.
13.
Bennett-GuerreroEZhaoYO’BrienSM. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA. 2010;304:1568-1575.
14.
LeviMvan der PollTBullerHR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698-2704.
15.
LevyJHSniecinskiRM. Prohemostatic treatment in cardiac surgery. Semin Thromb Hemost. 2012;38:237-243.
16.
SniecinskiRMLevyJH. Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg. 2011;142:662-667.
17.
BolligerDGörlingerKTanakaKA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010;113:1205-1219.
18.
EsperSALevyJHWatersJHWelsbyIJ. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg. 2014;118:731-743.
19.
StahlGLShernanSKSmithPKLevyJH. Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth Analg. 2012;115:759-771.
20.
TanakaKAKeyNSLevyJH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009;108:1433-1446.
21.
HollowayDSSummariaLSandesaraJVagherJPAlexanderJCCapriniJA. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost. 1988;59:62-67.
22.
RinderCSMathewJPRinderHMBonanJAultKASmithBR. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology. 1991;75:563-570.
23.
RinderCSBohnertJRinderHMMitchellJAultKHillmanR. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology. 1991;75:388-393.
24.
EdmundsLHJr.Managing fibrinolysis without aprotinin. Ann Thorac Surg. 2010;89:324-331.
25.
LeviMFriesDGombotzH. Prevention and treatment of coagulopathy in patients receiving massive transfusions. Vox Sang. 2011;101:154-174.
26.
GörlingerKDirkmannDHankeAA. Potential value of transfusion protocols in cardiac surgery. Curr Opin Anaesthesiol. 2013;26:230-243.
27.
SniecinskiRMChandlerWL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg. 2011;113:1319-1333.
28.
RozentalTShore-LessersonL. Pharmacologic management of coagulopathy in cardiac surgery: an update. J Cardiothorac Vasc Anesth. 2012;26:669-679.
29.
KarkoutiKMcCluskeySASyedSPazaratzCPoonawalaHCrowtherMA. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg. 2010;110:1533-1540.
30.
LevyJHSzlamFTanakaKASniecienskiRM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg. 2012;114:261-274.
31.
KarlssonMTernstromLHyllnerMBaghaeiFNilssonSJeppssonA. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion. 2008;48:2152-2158.
32.
NielsenVGCohenBMCohenE. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand. 2005;49:222-231.
33.
KarkoutiKCallumJCrowtherMA. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study. Anesth Analg. 2013;117:14-22.
34.
LevyJHTanakaKA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003;75:S715-S720.
35.
EsmonCT. The protein C pathway. Chest. 2003;124(3 suppl):26S-32S.
36.
EsmonCT. Coagulation and inflammation. J Endotoxin Res. 2003;9:192-198.
37.
RanucciM. The endothelial function in cardiac surgery. Minerva Anestesiol. 2006;72:503-506.
38.
EsmonCT. Inflammation and thrombosis. J Thromb Haemost. 2003;1:1343-1348.
British Committee for Standards in Haematology, StainsbyDMacLennanSThomasDIsaacJHamiltonPJ. Guidelines on the management of massive blood loss. Br J Haematol. 2006;135:634-641.
41.
SteinerMEDespotisGJ. Transfusion algorithms and how they apply to blood conservation: the high-risk cardiac surgical patient. Hematol Oncol Clin North Am. 2007;21:177-184.
42.
Society of Thoracic Surgeons Blood Conservation Guideline Task Force, FerrarisVAFerrarisSP. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(5 suppl):S27-S86.
43.
PerryDJFitzmauriceDAKitchenSMackieIJMallettS. Point-of-care testing in haemostasis. Br J Haematol. 2010;150:501-514.
44.
DarcyMDKantermanRYKleinhofferMA. Evaluation of coagulation tests as predictors of angiographic bleeding complications. Radiology. 1996;198:741-744.
45.
MunroJBoothANichollJ. Routine preoperative testing: a systematic review of the evidence. Health Technol Assess. 1997;1:i-iv; 1-62.
46.
ManningSCBesteDMcBrideTGoldbergA. An assessment of preoperative coagulation screening for tonsillectomy and adenoidectomy. Int J Pediatr Otorhinolaryngol. 1987;13:237-244.
47.
HourySGeorgeacCHayJMFingerhutABoudetMJ. A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research. Am J Surg. 1995;170:19-23.
48.
HaasTSpielmannNMauchJ. Comparison of thromboelastometry (ROTEM®) with standard plasmatic coagulation testing in paediatric surgery. Br J Anaesth. 2012;108:36-41.
49.
HaasTSpielmannNMauchJSpeerOSchmuggeMWeissM. Reproducibility of thrombelastometry (ROTEM®): point-of-care versus hospital laboratory performance. Scand J Clin Lab Invest. 2012;72:313-317.
50.
AvidanMSAlcockELDa FonsecaJ. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth. 2004;92:178-186.
51.
RoystonDvon KierS. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth. 2001;86:575-578.
52.
NuttallGAOliverWCSantrachPJ. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology. 2001;94:773-781; discussion 5A-6A.
53.
AkKIsbirCSTetikS. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg. 2009;24:404-410.
54.
WestbrookAJOlsenJBaileyMBatesJScullyMSalamonsenRF. Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study. Heart Lung Circ. 2009;18:277-288.
55.
WeberCFGörlingerKMeiningerD. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012;117:531-547.
56.
GörlingerKDirkmannDHankeAA. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology. 2011;115:1179-1191.
57.
HankeAAHeroldUDirkmannDTsagakisKJakobHGörlingerK. Thromboelastometry based early goal-directed coagulation management reduces blood transfusion requirements, adverse events, and costs in acute type a aortic dissection: a pilot study. Transfus Med Hemother. 2012;39:121-128.
58.
GirdauskasEKempfertJKuntzeT. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg. 2010;140:1117.e2-1124.e2.
59.
HertfelderHJBosMWeberDWinklerKHanflandPPreusseCJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost. 2005;31:426-440.
60.
TanakaKABolligerDVadlamudiRNimmoA. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth. 2012;26:1083-1093.
61.
WhitingDDiNardoJA. TEG and ROTEM: technology and clinical applications. Am J Hematol. 2014;89:228-232.
62.
SniecinskiRMKarkoutiKLevyJH. Managing clotting: a North American perspective. Curr Opin Anaesthesiol. 2012;25:74-79.
63.
MaquelinKNBerckmansRJNieuwlandR. Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998;115:1160-1165.
64.
WengerRKLukasiewiczHMikutaBSNiewiarowskiSEdmundsLHJr.Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1989;97:235-239.
HarrisonPMumfordA. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost. 2009;35:150-157.
67.
WeitzelNSWeitzelLBEppersonLEKarimpour-FordATranZVSeresT. Platelet mapping as part of modified thromboelastography (TEG®) in patients undergoing cardiac surgery and cardiopulmonary bypass. Anaesthesia. 2012;67:1158-1165.
68.
SchimmerCHamoudaKSommerSPOzkurMHainJLeyhR. The predictive value of multiple electrode platelet aggregometry (multiplate) in adult cardiac surgery. Thorac Cardiovasc Surg. 2013;61:733-743.
69.
OrlovDMcCluskeySASelbyRYipPPendergrastJKarkoutiK. Platelet dysfunction as measured by a point-of-care monitor is an independent predictor of high blood loss in cardiac surgery. Anesth Analg. 2014;118:257-263.
70.
GörlingerKFriesDDirkmannDWeberCFHankeAASchochlH. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother. 2012;39:104-113.
71.
StanworthSJGrant-CaseyJLoweD. The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion. 2011;51:62-70.
72.
StanworthSJWalshTSPrescottRJ. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care. 2011;15:R108.
73.
WelsbyIJTroughtonMPhillips-ButeB. The relationship of plasma transfusion from female and male donors with outcome after cardiac surgery. J Thorac Cardiovasc Surg. 2010;140:1353-1360.
74.
BjurstenHDardashtiAEderothPBrondénBAlgotssonL. Increased long-term mortality with plasma transfusion after coronary artery bypass surgery. Intensive Care Med. 2013;39:437-444.
75.
SaraniBDunkmanWJDeanLSonnadSRohrbachJIGraciasVH. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med. 2008;36:1114-1118.
76.
KhanSAPriyamvadaSArivarasuNAKhanSYusufiAN. Influence of green tea on enzymes of carbohydrate metabolism, antioxidant defense, and plasma membrane in rat tissues. Nutrition. 2007;23:687-695.
77.
GillRHerbertsonMVuylstekeA. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009;120:21-27.
78.
KarkoutiKBeattieWSArellanoR. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation. 2008;118:331-338.
GörlingerKBergmannLDirkmannD. Coagulation management in patients undergoing mechanical circulatory support. Best Pract Res Clin Anaesthesiol. 2012;26:179-198.
LevyJHAdkinsonNFJr.Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg. 2008;106:392-403.
83.
GottschlichGMGravleeGPGeorgitisJW. Adverse reactions to protamine sulfate during cardiac surgery in diabetic and non-diabetic patients. Ann Allergy. 1988;61:277-281.
84.
LevyJH. Anaphylactic/anaphylactoid reactions during cardiac surgery. J Clin Anesth. 1989;1:426-430.
DykewiczMSKimHWOrfanNYooTJLiebermanP. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immunol. 1994;93:117-125.
87.
CormackJGLevyJH. Adverse reactions to protamine. Coron Artery Dis. 1993;4:420-425.
88.
KimmelSESekeresMABerlinJAEllisonNDiSesaVJStromBL. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. J Am Coll Cardiol. 1998;32:1916-1922.
89.
KimmelSESekeresMABerlinJAGoldbergLRStromBL. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J Clin Epidemiol. 1998;51:1-10.
90.
SamuelT. Antibodies reacting with salmon and human protamines in sera from infertile men and from vasectomized men and monkeys. Clin Exp Immunol. 1977;30:181-187.
91.
WeilerJMGellhausMACarterJG. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol. 1990;85:713-719.
92.
MochizukiTOlsonPJSzlamFRamsayJGLevyJH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781-785.
93.
MittermayrMVelik-SalchnerCStalzerB. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study. Anesth Analg. 2009;108:743-750.
94.
CattaneoMHarrisASStrombergUMannucciPM. The effect of desmopressin on reducing blood loss in cardiac surgery—a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost. 1995;74:1064-1070.
95.
MannucciPMLeviM. Prevention and treatment of major blood loss. N Engl J Med. 2007;356:2301-2311.
96.
ManganoDTMiaoYVuylstekeA. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007;297:471-479.
97.
ManganoDTTudorICDietzelC, Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
98.
ShawADStafford-SmithMWhiteWD. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008;358:784-793.
99.
SkyringASingerATornyaP. Treatment of acute pancreatitis with trasylol: report of a controlled therapeutic trial. BMJ. 1965;2:627-629.
100.
LeviMCromheeckeMEde JongeE. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;354:1940-1947.
101.
SedrakyanATreasureTElefteriadesJA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442-448.
102.
FergussonDAHebertPCMazerCD. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-2331.
103.
KarkoutiKWijeysunderaDNYauTMMcCluskeySATaitGBeattieWS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg. 2010;110:21-29.
104.
HorrowJCAbramsJTVan RiperDFLambsonDLStorellaRJ. Ventilatory compliance after three sufentanil-pancuronium induction sequences. Anesthesiology. 1991;75:969-974.
105.
FremesSEWongBILeeE. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg. 1994;58:1580-1588.
106.
HenryDACarlessPAMoxeyAJ. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;(3):CD001886.
107.
LaupacisAFergussonD. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg. 1997;85:1258-1267.
108.
MartinKWiesnerGBreuerTLangeRTassaniP. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg. 2008;107:1783-1790.
109.
MurkinJMFalterFGrantonJYoungBBurtCChuM. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010;110:350-353.
110.
LeckerIWangDSRomaschinADPetersonMMazerCDOrserBA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest. 2012;122:4654-4666.
111.
BlomeMIsgroFKiesslingAH. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost. 2005;93:1101-1107.
112.
TernstromLRadulovicVKarlssonM. Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study. Thromb Res. 2010;126:e128-e133.
113.
Rahe-MeyerNPichlmaierMHaverichA. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth. 2009;102:785-792.
114.
Rahe-MeyerNSolomonCHankeA. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013;118:40-50.
115.
LeeSHLeeSMKimCS. Use of fibrin-based thromboelastometry for cryoprecipitate transfusion in cardiac surgery involving deep hypothermic circulatory arrest during cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2010;21:687-691.
116.
Rahe-MeyerNSolomonCTokunoML. Comparative assessment of coagulation changes induced by two different types of heart-lung machine. Artif Organs. 2010;34:3-12.
GodjeOHaushoferMLammPReichartB. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg. 1998;46:263-267.
119.
ShainoffJREstafanousFGYaredJPDiBelloPMKottke-MarchantKLoopFD. Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1994;108:437-445.
120.
GodjeOGallmeierUSchelianMGrunewaldMMairH. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg. 2006;54:26-33.
121.
KarkoutiKvon HeymannCJespersenCM. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg. 2013;146:927-939.
122.
SteinerMEKeyNSLevyJH. Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol. 2005;18:89-92.
123.
DiprosePHerbertsonMJO’ShaughnessyDGillRS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005;95:596-602.
124.
von HeymannCRedlichUJainU. Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. Crit Care Med. 2005;33:2241-2246.
125.
WarrenOMandalKHadjianastassiouV. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007;83:707-714.
126.
LeviMLevyJHAndersenHFTruloffD. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791-1800.
127.
TanakaKATaketomiTSzlamFCalatzisALevyJH. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg. 2008;106:732-738.
128.
KeyNSNegrierC. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370:439-448.
129.
HoffmanMDargaudY. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost. 2012;10:1478-1485.
130.
WojcikCSchymikMLCureEG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med. 2009;2:217-225.
131.
BolligerDSreeramGDuncanA. Prophylactic use of factor IX concentrate in a Jehovah’s Witness patient. Ann Thorac Surg. 2009;88:1666-1668.
132.
SarodeRMillingTJJrRefaaiMA. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-1243.
133.
DemeyereRGillardinSArnoutJStrengersPF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010;99:251-260.
134.
ArnekianVCamousJFattalSRezaiguia-DelclauxSNottinRStephanF. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg. 2012;15:382-389.
135.
HankeAAJochCGörlingerK. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth. 2013;110:764-772.
136.
BruceDNokesTJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12:R105.
137.
SchickKSFertmannJMJauchKWHoffmannJN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care. 2009;13:R191.
138.
DentaliFMarchesiCPierfranceschiMG. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011;106:429-438.
139.
SpiessBDGilliesBSChandlerWVerrierE. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth. 1995;9:168-173.
140.
SpaldingGJHartrumpfMSierigTOesbergNKirschkeCGAlbesJM. Cost reduction of perioperative coagulation management in cardiac surgery: value of “bedside” thrombelastography (ROTEM). Eur J Cardiothorac Surg. 2007;31:1052-1057.
